Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Non-Hodgkin 17Lymphoma, Follicular 14Lymphoma, Mantle-Cell 9Lymphoma 6Lymphoma, B-Cell, Marginal Zone 5Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 2Leukemia 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Leukemia, B-Cell 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Chromosome 17 deletion 1

Interventions

Allopurinol 2venetoclax 1rasburicase 1obinutuzumab 1Urate Oxidase 1Febuxostat 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Tumor Lysis Syndrome × Bendamustine Hydrochloride × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡